State Administration for Market Regulation and Standardization Administration of China have approved the following 6 mandatory national standards and 3 mandatory national standards with amendment.
State Administration for Market Regulation and Standardization Administration of China have approved the following 34 mandatory national standards and 1 mandatory national standard with amendment.
State Administration for Market Regulation and Standardization Administration of China have approved the following 353 national standards and 4 national standards with amendment.
State Administration for Market Regulation and Standardization Administration of China have approved the following 195 national standards and 1 national standard with amendment.
State Administration for Market Regulation and Standardization Administration of China have approved the following 109 national standards and 4 national standards with amendment.
State Administration for Market Regulation and Standardization Administration of China have approved the following 431 national standards and 2 national standards with amendment.
State Administration for Market Regulation and Standardization Administration of China have approved the following 373 national standards and 6 national standards with amendment.
State Administration for Market Regulation and Standardization Administration of China have approved the following 544 national standards and 4 national standards with amendment.
The State Planning Commission hasgiven its stamp of approval for thelaunching of the Longtan Hydropower Sta-tion,the largest one in the cascade develop-ment plan of 10 hydropower stations on theHongshui River in South...The State Planning Commission hasgiven its stamp of approval for thelaunching of the Longtan Hydropower Sta-tion,the largest one in the cascade develop-ment plan of 10 hydropower stations on theHongshui River in Southwest China.The project,located in GuangxiZhuang Autonomous Region,160 km fromPingguo aluminum base,250—280 kmfrom Liuzhou,Nanning and Guiyang,and670 km from Guangzhou,is designed to in-展开更多
Abemaciclib (Verzerio<span style="white-space:nowrap;"><sup><span style="font-family:Verdana, Helvetica, Arial;white-space:normal;background-color:#FFFFFF;">®</span>...Abemaciclib (Verzerio<span style="white-space:nowrap;"><sup><span style="font-family:Verdana, Helvetica, Arial;white-space:normal;background-color:#FFFFFF;">®</span></sup></span>) is a cell cycle inhibitor of both CDK4 and CDK6. In 2017, abemaciclib was approved by the Food and Drug Administration (FDA) and, in 2018 by the European Medicines Agency (EMA) for the treatment of postmenopausal women with hormone receptor positive (HR<sup>+</sup>), human epidermal growth factor receptor 2 negative (HER2<sup><span style="white-space:nowrap;"><sup><span style="white-space:nowrap;">−</span></sup></span></sup>) advanced breast cancer. In this mini-review, we provide a series of information for respectively their targets and its selectivity, results on preclinical trial, clinical phase I, II and III trials, and some perspectives. We also describe the batch and flow steps used for the synthesis of this cancer drug.展开更多
State Administration for Market Regulation and Standardization Administration of China have approved the following 450 national standards and 4 national standards with amendment.
State Administration for Market Regulation and Standardization Administration of China have approved the following 602 national standards and 1 national standard with amendment.
State Administration for Market Regulation and Standardization Administration of China have approved the following 530 national standards and 2 national standards with amendment.
文摘State Administration for Market Regulation and Standardization Administration of China have approved the following 6 mandatory national standards and 3 mandatory national standards with amendment.
文摘State Administration for Market Regulation and Standardization Administration of China have approved the following 34 mandatory national standards and 1 mandatory national standard with amendment.
文摘State Administration for Market Regulation and Standardization Administration of China have approved the following 353 national standards and 4 national standards with amendment.
文摘State Administration for Market Regulation and Standardization Administration of China have approved the following 195 national standards and 1 national standard with amendment.
文摘State Administration for Market Regulation and Standardization Administration of China have approved the following 109 national standards and 4 national standards with amendment.
文摘State Administration for Market Regulation and Standardization Administration of China have approved the following 431 national standards and 2 national standards with amendment.
文摘State Administration for Market Regulation and Standardization Administration of China have approved the following 373 national standards and 6 national standards with amendment.
文摘State Administration for Market Regulation and Standardization Administration of China have approved the following 544 national standards and 4 national standards with amendment.
文摘The State Planning Commission hasgiven its stamp of approval for thelaunching of the Longtan Hydropower Sta-tion,the largest one in the cascade develop-ment plan of 10 hydropower stations on theHongshui River in Southwest China.The project,located in GuangxiZhuang Autonomous Region,160 km fromPingguo aluminum base,250—280 kmfrom Liuzhou,Nanning and Guiyang,and670 km from Guangzhou,is designed to in-
文摘Abemaciclib (Verzerio<span style="white-space:nowrap;"><sup><span style="font-family:Verdana, Helvetica, Arial;white-space:normal;background-color:#FFFFFF;">®</span></sup></span>) is a cell cycle inhibitor of both CDK4 and CDK6. In 2017, abemaciclib was approved by the Food and Drug Administration (FDA) and, in 2018 by the European Medicines Agency (EMA) for the treatment of postmenopausal women with hormone receptor positive (HR<sup>+</sup>), human epidermal growth factor receptor 2 negative (HER2<sup><span style="white-space:nowrap;"><sup><span style="white-space:nowrap;">−</span></sup></span></sup>) advanced breast cancer. In this mini-review, we provide a series of information for respectively their targets and its selectivity, results on preclinical trial, clinical phase I, II and III trials, and some perspectives. We also describe the batch and flow steps used for the synthesis of this cancer drug.
文摘State Administration for Market Regulation and Standardization Administration of China have approved the following 450 national standards and 4 national standards with amendment.
文摘State Administration for Market Regulation and Standardization Administration of China have approved the following 602 national standards and 1 national standard with amendment.
文摘State Administration for Market Regulation and Standardization Administration of China have approved the following 530 national standards and 2 national standards with amendment.
